EARLY PROMISING DATA FROM THE PHASE 2 CLINICAL TRIAL OF THE VAXINE-CINNAGEN COVID-19 VACCINE

CinnaGen Co. announced that the results of preliminary analysis of data from the ongoing Phase 2 human clinical trial of the Vaxine-originated COVID-19 vaccine candidate were positive. This potential vaccine comprises a recombinant spike protein antigen formulated with Vaxine’s proprietary Advax-SM adjuvant. The Phase 2 study was a randomized, double-blind, placebo-controlled trial conducted in Iran on […]